KOD — Kodiak Sciences Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1468748 ·
Last close
$99.87
Market Cap
$6.28B
52W High
$104.00
52W Low
$10.94
ADV30
2,747,265
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -66,838,000 | -65,643,000 | 256,811,000 | 125,903,000 | 195,715,000 |
| Mar 2026 | 0 | — | -59,777,000 | -58,158,000 | 306,006,000 | 169,530,000 | 193,905,000 |
| Dec 2025 | 0 | — | -57,453,000 | -56,736,000 | 351,533,000 | 209,862,000 | 194,150,000 |
| Sep 2025 | 0 | — | -62,352,000 | -61,457,000 | 218,069,000 | 72,038,000 | 194,377,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-146,940,000
Investing CF
$-1,178,000
Financing CF
$178,797,000
CapEx
$-1,178,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.17
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,616,863,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-230,671,000
Pretax Income TTM
$-230,664,000
Interest Exp TTM
$0
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -234,388,000 | -229,967,000 | 351,533,000 | 194,150,000 | 157,383,000 | -136,008,000 |
| Dec 2024 | 0 | -186,849,000 | -176,207,000 | 335,578,000 | 185,290,000 | 150,288,000 | -117,319,000 |
| Dec 2023 | 0 | -277,321,000 | -260,491,000 | 479,372,000 | 213,591,000 | 265,781,000 | -154,183,000 |
| Dec 2022 | 0 | -341,379,000 | -333,823,000 | 666,628,000 | 230,461,000 | 436,167,000 | -206,459,000 |
TTM Snapshot
Revenues TTM
$4,556,000
NetIncome TTM
$-230,664,000
OpCashFlow TTM
—
Assets (Latest)
$306,006,000
Forward EPS
$-3.75
Max Pain — expiry 2026-10-16
max pain strike: $70.00 · spot: $99.87 · call oi: 12,869 · put oi: 13,868
Expected Move to 2026-10-16:
±$8.50
(8.51%) —
implied range
$91.37 –
$108.37
· ATM straddle on $100.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMVT | Immunovant, Inc. | $6.29B | $30.47 | — |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $6.62B | $14.62 | — |
| CGON | CG Oncology, Inc. | $5.66B | $63.82 | — |
| CRSP | CRISPR Therapeutics AG | $5.16B | $53.39 | — |
| SRRK | Scholar Rock Holding Corp | $5.14B | $42.19 | — |
News headlines (Yahoo Finance, 1h cache)
Kodiak Sciences (KOD) Could Be 7% Overvalued Following Late Stage Data Update
2026-10-08 19:12 · Yahoo
Kodiak Sciences (KOD) Stock Trades At A Premium On DAYBREAK Trial News
2026-10-08 15:13 · Yahoo
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
2026-10-07 11:00 · Yahoo
Kodiak Sciences’ Two Wet AMD Treatments Match Aflibercept in Phase III Study
2026-10-02 18:02 · Yahoo
This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
2026-10-02 15:00 · Yahoo
Kodiak Sciences More Than Doubles on Eye Disease Trial Results
2026-10-01 14:57 · Yahoo
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?
2026-09-30 12:05 · Yahoo
Why Kodiak Sciences Skyrocketed Today
2026-09-29 02:58 · Yahoo
KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’
2026-09-29 02:13 · Yahoo
Kodiak Sciences (KOD) Climbs Nearly 3x on Promising Wet AMD Trial
2026-09-28 23:14 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-09-30 16:29:20 | 2026-09-28 | Baker Bros. Advisors LP | Dir, 10% | P - Purchase | 72.57 | 807840 | 58625708 |
| 2026-09-30 16:30:05 | 2026-09-28 | Baker Bros. Advisors LP | Dir, 10% | P - Purchase | 83.58 | 418323 | 34963077 |